WO2001041704A3 - Method for the prevention and/or treatment of atherosclerosis - Google Patents

Method for the prevention and/or treatment of atherosclerosis Download PDF

Info

Publication number
WO2001041704A3
WO2001041704A3 PCT/US2000/033098 US0033098W WO0141704A3 WO 2001041704 A3 WO2001041704 A3 WO 2001041704A3 US 0033098 W US0033098 W US 0033098W WO 0141704 A3 WO0141704 A3 WO 0141704A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
atherosclerosis
lxr
prevention
provides
Prior art date
Application number
PCT/US2000/033098
Other languages
French (fr)
Other versions
WO2001041704A2 (en
Inventor
Carl P Sparrow
John G Ondeyka
Sheo Bux Singh
Original Assignee
Merck & Co Inc
Carl P Sparrow
John G Ondeyka
Sheo Bux Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Carl P Sparrow, John G Ondeyka, Sheo Bux Singh filed Critical Merck & Co Inc
Priority to JP2001542873A priority Critical patent/JP2003516327A/en
Priority to CA002392568A priority patent/CA2392568A1/en
Priority to EP00983963A priority patent/EP1239855A4/en
Priority to AU20647/01A priority patent/AU2064701A/en
Publication of WO2001041704A2 publication Critical patent/WO2001041704A2/en
Publication of WO2001041704A3 publication Critical patent/WO2001041704A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The instant invention provides a method for raising serum HDL cholesterol levels comprising administering a therapeutically effective amount of an LXR ligand to a patient in need of such treatment. It further provides a method for using an LXR ligand to stimulate expression of the ABC1 gene. LXR ligands can be used for preventing and treating atherosclerosis and related conditions.
PCT/US2000/033098 1999-12-13 2000-12-07 Method for the prevention and/or treatment of atherosclerosis WO2001041704A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001542873A JP2003516327A (en) 1999-12-13 2000-12-07 Prevention and / or treatment method of atherosclerosis
CA002392568A CA2392568A1 (en) 1999-12-13 2000-12-07 Method for the prevention and/or treatment of atherosclerosis
EP00983963A EP1239855A4 (en) 1999-12-13 2000-12-07 Method for the prevention and/or treatment of atherosclerosis
AU20647/01A AU2064701A (en) 1999-12-13 2000-12-07 Method for the prevention and/or treatment of atherosclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17040399P 1999-12-13 1999-12-13
US60/170,403 1999-12-13

Publications (2)

Publication Number Publication Date
WO2001041704A2 WO2001041704A2 (en) 2001-06-14
WO2001041704A3 true WO2001041704A3 (en) 2001-12-06

Family

ID=22619728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033098 WO2001041704A2 (en) 1999-12-13 2000-12-07 Method for the prevention and/or treatment of atherosclerosis

Country Status (5)

Country Link
EP (1) EP1239855A4 (en)
JP (1) JP2003516327A (en)
AU (1) AU2064701A (en)
CA (1) CA2392568A1 (en)
WO (1) WO2001041704A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (en) 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
EP1854880A1 (en) * 1999-03-15 2007-11-14 University of British Columbia Methods and reagents for modulating cholesterol levels
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
JP2003520780A (en) * 1999-09-01 2003-07-08 ユニバーシティ オブ ブリティッシュ コロンビア Compositions and methods for regulating HDL cholesterol and triglyceride levels
EP1203588A1 (en) * 2000-11-06 2002-05-08 Bayer Ag Sterol-independent regulation of ABC1 promoter via oncostatinM
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2003031408A2 (en) * 2001-10-08 2003-04-17 Eli Lilly And Company Tricyclic compounds useful for modulating lxr
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
WO2003082198A2 (en) * 2002-03-27 2003-10-09 Smithkline Beecham Corporation Methods of treatment with lxr modulators
AU2003256655A1 (en) 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2004050598A1 (en) * 2002-12-03 2004-06-17 Kowa Co., Ltd. Method for preparing acetylpodocarpic anhydride
TW200529845A (en) * 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
EP1806332A4 (en) 2004-10-27 2010-03-31 Daiichi Sankyo Co Ltd Benzene compound having 2 or more substituents
US8030335B2 (en) 2005-05-10 2011-10-04 Laboratoires Fournier S.A. Use of liver X receptor agonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
AU2018269568B2 (en) * 2017-05-18 2022-03-24 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
EA202191430A1 (en) * 2018-11-20 2021-11-29 Регенерон Фармасьютикалз, Инк. BIS-OCTAHYDROPHENANTHENETRENE CARBOXAMIDE DERIVATIVES AND THEIR PROTEIN CONJUGATES
EP3887401A2 (en) 2018-11-26 2021-10-06 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708055B2 (en) * 1996-02-02 1999-07-29 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
AU2002360620A1 (en) * 2001-12-20 2003-07-09 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] KAGAWA ET AL.: "Eicosapolyenoic acids of serum lipids of Japanese Islanders with low incidence of cardiovascular diseases", XP002944046, accession no. STN Database accession no. 97:180872 *
J. NUTR. SCI.VITAMINOL., vol. 28, no. 4, 1982, pages 441 - 453 *
See also references of EP1239855A4 *
WINDHOLZ ET AL.: "Prodocarpic Acid. 1,2,3,4,4a,9, 10,10a-Octahydro-6-hydroxy-1, 4a-demethyl-1-phenanthrenecarboxylic acid; 12-hydroxypodocarpa-1,11,13,-trein-16-oic acid", 1983, MERCK INDEX, EDS. MERCK DOHM & SHARP, RAHWAY, N.J., XP002944047 *

Also Published As

Publication number Publication date
EP1239855A4 (en) 2004-04-21
JP2003516327A (en) 2003-05-13
EP1239855A2 (en) 2002-09-18
WO2001041704A2 (en) 2001-06-14
CA2392568A1 (en) 2001-06-14
AU2064701A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
WO2001041704A3 (en) Method for the prevention and/or treatment of atherosclerosis
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
EP0908186A3 (en) Method for treating pain
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
PL307463A1 (en) Pharmaceutical agent especially for inhibiting osteoporosis and lowering cholesterol level in blood serum
GB9519661D0 (en) Fatty acid treatment
WO2005027842A8 (en) Combinations of drugs for the treatment of neoplasms
DE60239612D1 (en) MONODISPERSE MIXTURES AND METHOD FOR THE TREATMENT OF DIABETES
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
HK1053975A1 (en) Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
GB2422373A (en) Treatment of neurodegenerative conditions
HK1042825A1 (en) Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2003034996A3 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
WO2004017917A3 (en) Method for the prevention and/or treatment of atherosclerosis
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
EP1171616A4 (en) Method for enhancing myoblast migration and invasion in the context of gene therapy
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2001035899A3 (en) Inhibitors of helicobacter pylori induced gastrointestinal diseases
PL328924A1 (en) Method of treating abuse of substances

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000983963

Country of ref document: EP

Ref document number: 2392568

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20647/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 542873

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000983963

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000983963

Country of ref document: EP